Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results